董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| J. Patrick Mackin | 男 | Independent Director | 53 | 28.62万美元 | 未持股 | 2020-05-15 |
| Richard F. Wallman | 男 | Independent Director | 69 | 30.23万美元 | 未持股 | 2020-05-15 |
| Kevin C. O'Boyle | 男 | Independent Director | 64 | 31.40万美元 | 未持股 | 2020-05-15 |
| Elizabeth H. Weatherman | 女 | Independent Director | 60 | 31.17万美元 | 未持股 | 2020-05-15 |
| Gary D. Blackford | 男 | Independent Director | 62 | 29.65万美元 | 未持股 | 2020-05-15 |
| Amy S. Paul | 女 | Independent Director | 68 | 29.37万美元 | 未持股 | 2020-05-15 |
| Robert J. Palmisano | 男 | Director, President and Chief Executive Officer | 75 | 730.92万美元 | 未持股 | 2020-05-15 |
| John L. Miclot | 男 | Independent Director | 61 | 30.50万美元 | 未持股 | 2020-05-15 |
| David D. Stevens | 男 | Independent Director, Chairman | 66 | 36.52万美元 | 未持股 | 2020-05-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kevin D. Cordell | 男 | Executive Vice President, Chief Global Commercial Officer | 54 | 210.50万美元 | 未持股 | 2020-05-15 |
| J. Wesley Porter | 男 | Senior Vice President, Chief Compliance Officer | 50 | 未披露 | 未持股 | 2020-05-15 |
| Lance A. Berry | 男 | Executive Vice President, Chief Financial and Operations Officer | 47 | 238.99万美元 | 未持股 | 2020-05-15 |
| Peter S. Cooke | 男 | President, Emerging Markets, Australia and Japan | 55 | 未披露 | 未持股 | 2020-05-15 |
| Timothy L. Lanier | 男 | President, Upper Extremities | 58 | 未披露 | 未持股 | 2020-05-15 |
| Patrick Fisher | 男 | President, Lower Extremities | 46 | 未披露 | 未持股 | 2020-05-15 |
| Jason D. Asper | 男 | Senior Vice President, Chief Digital Officer | 45 | 130.37万美元 | 未持股 | 2020-05-15 |
| Julie D. Dewey | 女 | Senior Vice President, Chief Communications Officer | 58 | 未披露 | 未持股 | 2020-05-15 |
| Kevin C. Smith | 男 | Senior Vice President, Quality and Regulatory | 60 | 未披露 | 未持股 | 2020-05-15 |
| Barry J. Regan | 男 | Senior Vice President, Operations | 48 | 132.77万美元 | 未持股 | 2020-05-15 |
| Steven P. Wallace | 男 | President, International | 40 | 未披露 | 未持股 | 2020-05-15 |
| Jennifer S. Walker | 女 | Senior Vice President, Process Improvement | 52 | 未披露 | 未持股 | 2020-05-15 |
| Andrew C. Morton | 男 | Senior Vice President and Chief Human Resources Officer | 55 | 未披露 | 未持股 | 2020-05-15 |
| Robert J. Palmisano | 男 | Director, President and Chief Executive Officer | 75 | 730.92万美元 | 未持股 | 2020-05-15 |
| James A. Lightman | 男 | Senior Vice President, General Counsel and Secretary | 62 | 157.22万美元 | 未持股 | 2020-05-15 |
| Julie B. Andrews | 女 | Senior Vice President, Global Finance | 49 | 未披露 | 未持股 | 2020-05-15 |
董事简历
中英对照 | 中文 | 英文- J. Patrick Mackin
-
J. Patrick Mackin，他于2014年9月被任命为总裁兼首席执行官。他于2014年10月被任命到董事会。他于2015年5月被任命为主席。他在医疗器械行业有着20年以上的经验。加入CryoLife公司之前，他曾担任Cardiac Rhythm Disease Management公司（Medtronic公司的最大的运营部门）的总裁。任职Medtronic公司期间，他此前曾担任西欧血管副总裁、血管内业务部门的副总裁兼总经理。2002年加入Medtronic公司之前，他曾任职Genzyme公司6年，也曾担任心血管手术业务单元的高级副总裁兼总经理，以及销售、外科产品部门的董事。加入Genzyme公司之前，他曾任职Deknatel/Snowden-Pencer公司4年，担任多种职务，也曾担任美国陆军中尉3年。他持有Northwestern University’s Kellogg Graduate School of Management的工商管理硕士学位，毕业于the U.S. Military Academy at West Point。
J. Patrick Mackin was named President and Chief Executive Officer of CryoLife in September 2014. He was appointed to the CryoLife Board of Directors in October 2014 and he was appointed Chairman of the Board of Directors in April 2015. Mr. Mackin has more than 25 years of experience in the medical device industry. Prior to joining CryoLife, Mr. Mackin served as President of Cardiac Rhythm Disease Management, the then largest operating division of Medtronic plc NYSE: MDT ("Medtronic"), from August 2007 to August 2014. At Medtronic, he previously held the positions of Vice President, Vascular, Western Europe and Vice President and General Manager, Endovascular Business Unit. Prior to joining Medtronic in 2002 Mr. Mackin worked for six years at Genzyme, Inc., serving as Senior Vice President and General Manager for the Cardiovascular Surgery Business Unit and as Director of Sales, Surgical Products division. Before joining Genzyme, Inc., Mr. Mackin spent four years at Deknatel/Snowden-Pencer, Inc. in various roles and three years as a First Lieutenant in the U.S. Army. Mr. Mackin has served as a director of Opsens, Inc. (TSXV: OPS and OTCQX: OPSSF), a fiber optic sensors manufacturer, since 2016. Mr. Mackin served as a director of Wright Medical Group N.V. (NASDAQ: WMGI), a global medical device company focused on extremities and biologics, from July 2018 until November 2020 when Wright Medical Group N.V. was acquired by Stryker Corporation (NYSE: SYK). Mr. Mackin received an MBA from the Kellogg Graduate School of Management at Northwestern University and is a graduate of the U.S. Military Academy at West Point. - J. Patrick Mackin，他于2014年9月被任命为总裁兼首席执行官。他于2014年10月被任命到董事会。他于2015年5月被任命为主席。他在医疗器械行业有着20年以上的经验。加入CryoLife公司之前，他曾担任Cardiac Rhythm Disease Management公司（Medtronic公司的最大的运营部门）的总裁。任职Medtronic公司期间，他此前曾担任西欧血管副总裁、血管内业务部门的副总裁兼总经理。2002年加入Medtronic公司之前，他曾任职Genzyme公司6年，也曾担任心血管手术业务单元的高级副总裁兼总经理，以及销售、外科产品部门的董事。加入Genzyme公司之前，他曾任职Deknatel/Snowden-Pencer公司4年，担任多种职务，也曾担任美国陆军中尉3年。他持有Northwestern University’s Kellogg Graduate School of Management的工商管理硕士学位，毕业于the U.S. Military Academy at West Point。
- J. Patrick Mackin was named President and Chief Executive Officer of CryoLife in September 2014. He was appointed to the CryoLife Board of Directors in October 2014 and he was appointed Chairman of the Board of Directors in April 2015. Mr. Mackin has more than 25 years of experience in the medical device industry. Prior to joining CryoLife, Mr. Mackin served as President of Cardiac Rhythm Disease Management, the then largest operating division of Medtronic plc NYSE: MDT ("Medtronic"), from August 2007 to August 2014. At Medtronic, he previously held the positions of Vice President, Vascular, Western Europe and Vice President and General Manager, Endovascular Business Unit. Prior to joining Medtronic in 2002 Mr. Mackin worked for six years at Genzyme, Inc., serving as Senior Vice President and General Manager for the Cardiovascular Surgery Business Unit and as Director of Sales, Surgical Products division. Before joining Genzyme, Inc., Mr. Mackin spent four years at Deknatel/Snowden-Pencer, Inc. in various roles and three years as a First Lieutenant in the U.S. Army. Mr. Mackin has served as a director of Opsens, Inc. (TSXV: OPS and OTCQX: OPSSF), a fiber optic sensors manufacturer, since 2016. Mr. Mackin served as a director of Wright Medical Group N.V. (NASDAQ: WMGI), a global medical device company focused on extremities and biologics, from July 2018 until November 2020 when Wright Medical Group N.V. was acquired by Stryker Corporation (NYSE: SYK). Mr. Mackin received an MBA from the Kellogg Graduate School of Management at Northwestern University and is a graduate of the U.S. Military Academy at West Point.
- Richard F. Wallman
-
Richard F. Wallman，1995年3月至2003年7月，他曾经担任多元化的工业技术和制造公司Honeywell国际公司首席财务官兼高级副总裁，其前身为联信公司。他还曾担任过IBM和克莱斯勒公司高级财务职位，现任Convergys公司，Extended Stay America公司，Tornier N.V.，和Charles River Laboratories国际公司董事，2002年至2012年，曾经担任Ariba公司董事，2010年至2013年曾任德纳控股公司董事。2003年至2009年，曾任Hayes-Lemmerz国际和李尔公司董事。
Richard F. Wallman,served as the Senior Vice President and Chief Financial Officer of Honeywell International, Inc., a diversified technology company, and AlliedSignal, Inc. (prior to its merger with Honeywell). He is also a member of the boards of directors of Roper Technologies, Inc. and CECO Environmental Corp. and in the past five years has served as a member of the boards of Spirit Airlines, Inc., Smile Direct Club, and Extended Stay America. Mr. Wallman has been a director since January 2011. - Richard F. Wallman，1995年3月至2003年7月，他曾经担任多元化的工业技术和制造公司Honeywell国际公司首席财务官兼高级副总裁，其前身为联信公司。他还曾担任过IBM和克莱斯勒公司高级财务职位，现任Convergys公司，Extended Stay America公司，Tornier N.V.，和Charles River Laboratories国际公司董事，2002年至2012年，曾经担任Ariba公司董事，2010年至2013年曾任德纳控股公司董事。2003年至2009年，曾任Hayes-Lemmerz国际和李尔公司董事。
- Richard F. Wallman,served as the Senior Vice President and Chief Financial Officer of Honeywell International, Inc., a diversified technology company, and AlliedSignal, Inc. (prior to its merger with Honeywell). He is also a member of the boards of directors of Roper Technologies, Inc. and CECO Environmental Corp. and in the past five years has served as a member of the boards of Spirit Airlines, Inc., Smile Direct Club, and Extended Stay America. Mr. Wallman has been a director since January 2011.
- Kevin C. O'Boyle
-
Kevin C. O'Boyle，2010年6月至今，担任本公司董事。2012年11月，他担任Tornier的临时副董事长，任期约一年。2010年12月至2011年10月，他担任Advanced BioHealing的高级副总裁、首席财务官，这是一个医疗器械公司，在2011年5月被Shire PLC收购。2003年1月至2009年12月，他担任NuVasive的首席财务官，这是一个医疗器械公司，在2004年5月完成首次公开发行。此前，他在ChromaVision Medical Systems工作了6年，担任过各种职务，其中包括首席财务官、首席运营官，这是专注于肿瘤市场的医疗器械上市公司。他曾在Albert Fisher North America工作了7年，担任过多个职务，其中包括首席财务官、高级运营副总裁，这是国际性的食品上市公司。他目前是上市公司GenMark Diagnostics、ZELTIQ Aesthetics，和 Durata Therapeutics的董事。他在Rochester Institute of Technology获得会计学士学位，并在University of California Los Angeles, John E. Anderson Graduate Business School成功完成了Executive Management Program课程。
Kevin C. O'Boyle is one of Wright Medical Group N.V. directors and has served as a director since June 2010. In November 2012 Mr. O'Boyle served as Interim Vice Chairman of Tornier, a position he held for about a year. From December 2010 to October 2011 Mr. O'Boyle served as Senior Vice President and Chief Financial Officer of Advanced BioHealing Inc., a medical device company which was acquired by Shire PLC in May 2011. From January 2003 until December 2009 Mr. O'Boyle served as the Chief Financial Officer of NuVasive, Inc., a medical device company that completed its initial public offering in May 2004. Prior to that time, Mr. O'Boyle served in various positions during his six years with ChromaVision Medical Systems, Inc., a publicly held medical device company specializing in the oncology market, including as its Chief Financial Officer and Chief Operating Officer. Mr. O'Boyle also held various positions during his seven years with Albert Fisher North America, Inc., a publicly held international food company, including Chief Financial Officer and Senior Vice President of Operations. Mr. O'Boyle currently serves on the board of directors of GenMark Diagnostics, Inc., ZELTIQ Aesthetics, Inc. and Durata Therapeutics, Inc., all publicly traded companies. Mr. O'Boyle received a Bachelor of Science in Accounting from the Rochester Institute of Technology and successfully completed the Executive Management Program at the University of California Los Angeles, John E. Anderson Graduate Business School. - Kevin C. O'Boyle，2010年6月至今，担任本公司董事。2012年11月，他担任Tornier的临时副董事长，任期约一年。2010年12月至2011年10月，他担任Advanced BioHealing的高级副总裁、首席财务官，这是一个医疗器械公司，在2011年5月被Shire PLC收购。2003年1月至2009年12月，他担任NuVasive的首席财务官，这是一个医疗器械公司，在2004年5月完成首次公开发行。此前，他在ChromaVision Medical Systems工作了6年，担任过各种职务，其中包括首席财务官、首席运营官，这是专注于肿瘤市场的医疗器械上市公司。他曾在Albert Fisher North America工作了7年，担任过多个职务，其中包括首席财务官、高级运营副总裁，这是国际性的食品上市公司。他目前是上市公司GenMark Diagnostics、ZELTIQ Aesthetics，和 Durata Therapeutics的董事。他在Rochester Institute of Technology获得会计学士学位，并在University of California Los Angeles, John E. Anderson Graduate Business School成功完成了Executive Management Program课程。
- Kevin C. O'Boyle is one of Wright Medical Group N.V. directors and has served as a director since June 2010. In November 2012 Mr. O'Boyle served as Interim Vice Chairman of Tornier, a position he held for about a year. From December 2010 to October 2011 Mr. O'Boyle served as Senior Vice President and Chief Financial Officer of Advanced BioHealing Inc., a medical device company which was acquired by Shire PLC in May 2011. From January 2003 until December 2009 Mr. O'Boyle served as the Chief Financial Officer of NuVasive, Inc., a medical device company that completed its initial public offering in May 2004. Prior to that time, Mr. O'Boyle served in various positions during his six years with ChromaVision Medical Systems, Inc., a publicly held medical device company specializing in the oncology market, including as its Chief Financial Officer and Chief Operating Officer. Mr. O'Boyle also held various positions during his seven years with Albert Fisher North America, Inc., a publicly held international food company, including Chief Financial Officer and Senior Vice President of Operations. Mr. O'Boyle currently serves on the board of directors of GenMark Diagnostics, Inc., ZELTIQ Aesthetics, Inc. and Durata Therapeutics, Inc., all publicly traded companies. Mr. O'Boyle received a Bachelor of Science in Accounting from the Rochester Institute of Technology and successfully completed the Executive Management Program at the University of California Los Angeles, John E. Anderson Graduate Business School.
- Elizabeth H. Weatherman
-
Elizabeth H. Weatherman，2006年7月至今，担任本公司的董事。本公司与某些本公司股票持有人之间订立了证券持有人协议，她因而被任命为董事。关于该证券持有人协议的更多信息，请参考以下关于Board Structure and Composition的讨论。她目前是Warburg Pincus & Co.的普通合伙人，以及Warburg Pincus LLC的董事总经理、执行管理小组成员。她于1988年加入Warburg Pincus，目前负责其美国医疗保健行业的投资业务。Warburg Pincus LLC 和 Warburg Pincus & Co.是Warburg Pincus的旗下公司，在此份委托书中统称为Warburg Pincus，它是本公司的大股东，截止2014年5月1日，拥有本公司近22.1%的普通流通股。她现在是一些私营公司的董事。在过去的5年，她担任上市公司 ev3，及其它一些私营公司的董事。另外，5年之前，她曾在医疗器械行业的一些上市公司担任董事。她在Stanford Graduate School of Business获得工商管理硕士学位，在Mount Holyoke College获得学士学位。
Elizabeth H. Weatherman,has served on Board of Directors since February 2022. She has been a Special Limited Partner of Warburg Pincus since January 2016. Ms. Weatherman joined Warburg Pincus in 1988 and led the firm's Healthcare Group from 2008 to 2015. She was also previously a Managing Director and a member of the firm's Executive Management Group. Ms. Weatherman serves as a director of Nevro Corp. and Stanford Health Care. She serves as a trustee of Stanford University and as a trustee and chair of the Investment Committee of Mount Holyoke College. Ms. Weatherman received a BA in English from Mount Holyoke College and holds an MBA from the Stanford Graduate School of Business. - Elizabeth H. Weatherman，2006年7月至今，担任本公司的董事。本公司与某些本公司股票持有人之间订立了证券持有人协议，她因而被任命为董事。关于该证券持有人协议的更多信息，请参考以下关于Board Structure and Composition的讨论。她目前是Warburg Pincus & Co.的普通合伙人，以及Warburg Pincus LLC的董事总经理、执行管理小组成员。她于1988年加入Warburg Pincus，目前负责其美国医疗保健行业的投资业务。Warburg Pincus LLC 和 Warburg Pincus & Co.是Warburg Pincus的旗下公司，在此份委托书中统称为Warburg Pincus，它是本公司的大股东，截止2014年5月1日，拥有本公司近22.1%的普通流通股。她现在是一些私营公司的董事。在过去的5年，她担任上市公司 ev3，及其它一些私营公司的董事。另外，5年之前，她曾在医疗器械行业的一些上市公司担任董事。她在Stanford Graduate School of Business获得工商管理硕士学位，在Mount Holyoke College获得学士学位。
- Elizabeth H. Weatherman,has served on Board of Directors since February 2022. She has been a Special Limited Partner of Warburg Pincus since January 2016. Ms. Weatherman joined Warburg Pincus in 1988 and led the firm's Healthcare Group from 2008 to 2015. She was also previously a Managing Director and a member of the firm's Executive Management Group. Ms. Weatherman serves as a director of Nevro Corp. and Stanford Health Care. She serves as a trustee of Stanford University and as a trustee and chair of the Investment Committee of Mount Holyoke College. Ms. Weatherman received a BA in English from Mount Holyoke College and holds an MBA from the Stanford Graduate School of Business.
- Gary D. Blackford
-
Gary D. Blackford自2016年8月起担任Obalon Therapeutics, Inc.的董事之一。从2002年到2015年2月，他担任Universal Hospital Services, Inc.的董事会主席兼首席执行官。纽交所：UHS是一家领先的医疗技术外包和医疗保健行业服务提供商。从2001年到2002年，他担任therapeutic Health Services, Inc.（专业制药和健康服务公司）的首席执行官。从1999年到2001年，他也是ShopforSchool, Inc.（在线零售商）的首席执行官。Blackford先生自2014年起担任Avanos Medical, Inc.（纽约证券交易所：AVNS）的董事（自2020年起担任董事长），自2017年起担任明尼苏达州儿童医院和诊所（自2020年起担任董事长），自2022年2月起担任Lifespace Communities, Inc.（非营利组织）的董事。2008年至2020年，他担任Wright Medical Group, N.V。（纳斯达克代码：WMGI）的董事；2016年至2020年，他担任PipelineRX, Inc.的董事。
Gary D. Blackford,has served as one of Reshape Lifesciences Inc. directors since August 2016. From 2002 until February 2015, Mr. Blackford was the Chairman of the Board and Chief Executive Officer of Universal Hospital Services, Inc. (NYSE: UHS), a leading nationwide provider of medical technology outsourcing and services to the health care industry. Mr. Blackford was the Chief Executive Officer of Curative Health Services, Inc., a specialty pharmacy and health services company, from 2001 to 2002. He was also the Chief Executive Officer of ShopforSchool, Inc., an online retailer, from 1999 to 2001. Mr. Blackford has also been a director of Avanos Medical, Inc. (NYSE: AVNS) since 2014 (and Chairman since 2020), Children's Hospitals and Clinics of Minnesota since 2017 (and Chairman since 2020), and Lifespace Communities, Inc., a not-for-profit organization, since February 2022. He was a director of Wright Medical Group, N.V. (NASDAQ: WMGI) from 2008 to 2020 and PipelineRX, Inc. from 2016 to 2020. - Gary D. Blackford自2016年8月起担任Obalon Therapeutics, Inc.的董事之一。从2002年到2015年2月，他担任Universal Hospital Services, Inc.的董事会主席兼首席执行官。纽交所：UHS是一家领先的医疗技术外包和医疗保健行业服务提供商。从2001年到2002年，他担任therapeutic Health Services, Inc.（专业制药和健康服务公司）的首席执行官。从1999年到2001年，他也是ShopforSchool, Inc.（在线零售商）的首席执行官。Blackford先生自2014年起担任Avanos Medical, Inc.（纽约证券交易所：AVNS）的董事（自2020年起担任董事长），自2017年起担任明尼苏达州儿童医院和诊所（自2020年起担任董事长），自2022年2月起担任Lifespace Communities, Inc.（非营利组织）的董事。2008年至2020年，他担任Wright Medical Group, N.V。（纳斯达克代码：WMGI）的董事；2016年至2020年，他担任PipelineRX, Inc.的董事。
- Gary D. Blackford,has served as one of Reshape Lifesciences Inc. directors since August 2016. From 2002 until February 2015, Mr. Blackford was the Chairman of the Board and Chief Executive Officer of Universal Hospital Services, Inc. (NYSE: UHS), a leading nationwide provider of medical technology outsourcing and services to the health care industry. Mr. Blackford was the Chief Executive Officer of Curative Health Services, Inc., a specialty pharmacy and health services company, from 2001 to 2002. He was also the Chief Executive Officer of ShopforSchool, Inc., an online retailer, from 1999 to 2001. Mr. Blackford has also been a director of Avanos Medical, Inc. (NYSE: AVNS) since 2014 (and Chairman since 2020), Children's Hospitals and Clinics of Minnesota since 2017 (and Chairman since 2020), and Lifespace Communities, Inc., a not-for-profit organization, since February 2022. He was a director of Wright Medical Group, N.V. (NASDAQ: WMGI) from 2008 to 2020 and PipelineRX, Inc. from 2016 to 2020.
- Amy S. Paul
-
Amy S. Paul自2008年以来担任我们的董事。她在2008年（在C.R. Bard, Inc.（医疗设备公司）的26年的职业生涯后）退休，最近自2003年以来担任国际集团副总裁。她从1982年到2003年在C.R. Bard, Inc.担任过许多职位，包括Bard Access Systems, Inc.的总裁，Bard Endoscopic Technologies（内窥镜技术）的总裁，Bard Ventures的副总裁兼业务经理，Bard Cardiopulmonary Division（心肺部门）的营销副总裁，Davol Inc.的营销经理和Davol Inc.的高级产品经理。她是Derma Sciences, Inc.（上市公司）的董事，Viking Systems, Inc.（上市公司）的董事，直到2012年10月它被Conmed Corporation收购，从2010年到2013年是the Northwest Commission on Colleges and Universities的专员，服务于Westminster College的President's Innovation Network（总裁创新网络）。
Amy S. Paul joined our board of directors as a non-executive director in October 2015 in connection with the Wright/Tornier merger. Ms. Paul was a member of the board of directors of Wright Medical Group, Inc. from 2008 to 2015. Ms. Paul retired in 2008 following a 26-year career with C.R. Bard, Inc., a medical device company, most recently serving as the Group Vice President-International since 2003. She served in various positions at C.R. Bard, Inc. from 1982 to 2003 including President of Bard Access Systems, Inc., President of Bard Endoscopic Technologies, Vice President and Business Manager of Bard Ventures, Vice President of Marketing of Bard Cardiopulmonary Division, Marketing Manager for Davol Inc., and Senior Product Manager for Davol Inc. Ms. Paul previously served on the board of directors of Derma Sciences, Inc., a publicly held company acquired by Integra LifeSciences Holdings Corporation, Viking Systems, Inc., a publicly held company acquired by Conmed Corporation, and was a commissioner of the Northwest Commission on Colleges and Universities from 2010 to 2013. Ms. Paul serves on the President’s Innovation Network at Westminster College. - Amy S. Paul自2008年以来担任我们的董事。她在2008年（在C.R. Bard, Inc.（医疗设备公司）的26年的职业生涯后）退休，最近自2003年以来担任国际集团副总裁。她从1982年到2003年在C.R. Bard, Inc.担任过许多职位，包括Bard Access Systems, Inc.的总裁，Bard Endoscopic Technologies（内窥镜技术）的总裁，Bard Ventures的副总裁兼业务经理，Bard Cardiopulmonary Division（心肺部门）的营销副总裁，Davol Inc.的营销经理和Davol Inc.的高级产品经理。她是Derma Sciences, Inc.（上市公司）的董事，Viking Systems, Inc.（上市公司）的董事，直到2012年10月它被Conmed Corporation收购，从2010年到2013年是the Northwest Commission on Colleges and Universities的专员，服务于Westminster College的President's Innovation Network（总裁创新网络）。
- Amy S. Paul joined our board of directors as a non-executive director in October 2015 in connection with the Wright/Tornier merger. Ms. Paul was a member of the board of directors of Wright Medical Group, Inc. from 2008 to 2015. Ms. Paul retired in 2008 following a 26-year career with C.R. Bard, Inc., a medical device company, most recently serving as the Group Vice President-International since 2003. She served in various positions at C.R. Bard, Inc. from 1982 to 2003 including President of Bard Access Systems, Inc., President of Bard Endoscopic Technologies, Vice President and Business Manager of Bard Ventures, Vice President of Marketing of Bard Cardiopulmonary Division, Marketing Manager for Davol Inc., and Senior Product Manager for Davol Inc. Ms. Paul previously served on the board of directors of Derma Sciences, Inc., a publicly held company acquired by Integra LifeSciences Holdings Corporation, Viking Systems, Inc., a publicly held company acquired by Conmed Corporation, and was a commissioner of the Northwest Commission on Colleges and Universities from 2010 to 2013. Ms. Paul serves on the President’s Innovation Network at Westminster College.
- Robert J. Palmisano
-
Robert J. Palmisano，担任总裁兼首席执行官，并于2011年9月起担任Wright Medical Group, Inc.纳斯达克：WMGI的董事会执行董事和董事会成员，直至2020年11月其被史赛克公司（NYSE：SYK）收购。Palmisano先生于2008年4月至2010年7月被Covidien plc收购时担任ev3 Inc.的总裁兼首席执行官。Palmisano先生于2003年4月至2007年4月被Advanced Medical Optics，Inc.收购时担任IntraLase Corp.的总裁兼首席执行官。在加入IntraLase之前，Palmisano先生于2001年4月至2003年4月担任MacroChem Corporation的总裁兼首席执行官。Palmisano先生于2020年12月至今担任Priveterra Acquisition Corp.（纳斯达克：PMGMU）的董事会主席。Palmisano先生此前曾担任Avedro, Inc.董事会主席，并在ev3 Inc.、Osteotech，Inc.和Abbott Medical Optics，Inc.（均为上市公司）以及博士伦（Bausch & Lomb）（一家私营公司）的董事会任职。Palmisano先生拥有普罗维登斯学院政治学学士学位。
Robert J. Palmisano served as President and Chief Executive Officer, and as the Executive Director of the Board of Directors and Board Member of Wright Medical Group, Inc. Nasdaq: WMGI from September 2011 until its acquisition by Stryker Corporation (NYSE: SYK) in November 2020. Mr. Palmisano served as President and Chief Executive Officer of ev3 Inc. from April 2008 to July 2010 when it was acquired by Covidien plc. Mr. Palmisano was President and Chief Executive Officer of IntraLase Corp. from April 2003 to April 2007 when it was acquired by Advanced Medical Optics, Inc. Before joining IntraLase, Mr. Palmisano was President and Chief Executive Officer of MacroChem Corporation from April 2001 to April 2003. Mr. Palmisano has served as Chairman of the Board of Priveterra Acquisition Corp. (Nasdaq: PMGMU) from December 2020 to present. Mr. Palmisano previously served as the Chairman of the Board of Avedro, Inc., and on the board of directors of ev3 Inc., Osteotech, Inc. and Abbott Medical Optics, Inc., all publicly held companies, and Bausch & Lomb, a privately held company. Mr. Palmisano holds a B.A. in Political Science from Providence College. - Robert J. Palmisano，担任总裁兼首席执行官，并于2011年9月起担任Wright Medical Group, Inc.纳斯达克：WMGI的董事会执行董事和董事会成员，直至2020年11月其被史赛克公司（NYSE：SYK）收购。Palmisano先生于2008年4月至2010年7月被Covidien plc收购时担任ev3 Inc.的总裁兼首席执行官。Palmisano先生于2003年4月至2007年4月被Advanced Medical Optics，Inc.收购时担任IntraLase Corp.的总裁兼首席执行官。在加入IntraLase之前，Palmisano先生于2001年4月至2003年4月担任MacroChem Corporation的总裁兼首席执行官。Palmisano先生于2020年12月至今担任Priveterra Acquisition Corp.（纳斯达克：PMGMU）的董事会主席。Palmisano先生此前曾担任Avedro, Inc.董事会主席，并在ev3 Inc.、Osteotech，Inc.和Abbott Medical Optics，Inc.（均为上市公司）以及博士伦（Bausch & Lomb）（一家私营公司）的董事会任职。Palmisano先生拥有普罗维登斯学院政治学学士学位。
- Robert J. Palmisano served as President and Chief Executive Officer, and as the Executive Director of the Board of Directors and Board Member of Wright Medical Group, Inc. Nasdaq: WMGI from September 2011 until its acquisition by Stryker Corporation (NYSE: SYK) in November 2020. Mr. Palmisano served as President and Chief Executive Officer of ev3 Inc. from April 2008 to July 2010 when it was acquired by Covidien plc. Mr. Palmisano was President and Chief Executive Officer of IntraLase Corp. from April 2003 to April 2007 when it was acquired by Advanced Medical Optics, Inc. Before joining IntraLase, Mr. Palmisano was President and Chief Executive Officer of MacroChem Corporation from April 2001 to April 2003. Mr. Palmisano has served as Chairman of the Board of Priveterra Acquisition Corp. (Nasdaq: PMGMU) from December 2020 to present. Mr. Palmisano previously served as the Chairman of the Board of Avedro, Inc., and on the board of directors of ev3 Inc., Osteotech, Inc. and Abbott Medical Optics, Inc., all publicly held companies, and Bausch & Lomb, a privately held company. Mr. Palmisano holds a B.A. in Political Science from Providence College.
- John L. Miclot
-
John L. Miclot， 曾担任公司董事并从2011年12月起担任公司总裁和首席执行官。加入公司之前，他从2010年3月到2011年3月担任华平驻企高管；从2008年11月开始担任CCS医药公司（一家华平控股的为慢性疾病患者提供产品和服务的供应商）总裁和首席执行官，直到2010年3月根据美国破产法第11章的保护，公司进行财务重组和合并才退休。从2003年到2008年他担任伟康公司总裁和首席执行官，直到伟康公司被皇家飞利浦收购。从2003年到2008年他担任飞利浦家庭医疗保健解决方案首席执行官，当时正值伟康公司被皇家飞利浦收购。他1998年加入伟康公司，正值伟康公司收购Healthdyne技术有限公司（一家医疗设备公司）。从1995年到1998年他担任Healthdyne公司销售与市场部高级副总裁。在此之前，他在Medex公司，美达，巴克斯特Edwards和DeRoyal产业担任多个销售与市场职位。他现在是赖特医疗集团有限公司和登士柏国际公司董事以及呼吸技术公司董事长。他也是匹兹堡动物园及PPG水族馆和汉堡王癌症关怀中心董事。他持有爱荷华大学市场学士学位。
John L. Miclot joined our board of directors as a non-executive director in October 2015 in connection with the Wright/Tornier merger. Mr. Miclot was a member of the board of directors of Wright Medical Group, Inc. from 2007 to 2015. Mr. Miclot has served as President and Chief Executive Officer and a member of the board of directors of LinguaFlex, Inc., a medical device company focused on treatment of sleep disordered breathing, since August 2015. From December 2011 to December 2014 he served as Chief Executive Officer and a member of the board of directors of Tengion Inc., a publicly held company that focused on organ and cell regeneration. Prior to joining Tengion, Mr. Miclot was an Executive-in Residence at Warburg Pincus, LLC. From 2008 to 2010 he was President and Chief Executive Officer of CCS Medical, Inc., a provider of products and services for patients with chronic diseases. From 2003 until 2008 he served as President and Chief Executive Officer of Respironics, Inc., a provider of sleep and respiratory products, and prior to such time, served in various positions at Respironics, Inc. from 1998 to 2003 including Chief Strategic Officer and President of the Homecare Division. From 1995 to 1998 he served as Senior Vice President, Sales and Marketing of Healthdyne Technologies, Inc., a medical device company that was acquired by Respironics, Inc. in 1998. Mr. Miclot spent the early part of his medical career at DeRoyal Industries, Inc., Baxter International Inc., Ohmeda Medical, Inc. and Medix Inc. Mr. Miclot serves as a director of the Pittsburgh Zoo and PPG Aquarium, charitable and educational institutions, serves on the University of Iowa Tippie College of Business board of advisors and serves as an industrial advisor to EQT Partners, an investment company. Mr. Miclot previously served as Chairman and a member of the board of directors of Breathe Technologies, Inc., a privately held company, prior to its acquisition by Hill-Rom Holdings, Inc. in September 2019. Mr. Miclot previously served on the board of directors of DENTSPLY International Inc., a dental products company, prior to its merger with Sirona Dental Systems, Inc. in February 2016 and ev3 Inc., a global endovascular device company, prior to the sale of the company in 2010. - John L. Miclot， 曾担任公司董事并从2011年12月起担任公司总裁和首席执行官。加入公司之前，他从2010年3月到2011年3月担任华平驻企高管；从2008年11月开始担任CCS医药公司（一家华平控股的为慢性疾病患者提供产品和服务的供应商）总裁和首席执行官，直到2010年3月根据美国破产法第11章的保护，公司进行财务重组和合并才退休。从2003年到2008年他担任伟康公司总裁和首席执行官，直到伟康公司被皇家飞利浦收购。从2003年到2008年他担任飞利浦家庭医疗保健解决方案首席执行官，当时正值伟康公司被皇家飞利浦收购。他1998年加入伟康公司，正值伟康公司收购Healthdyne技术有限公司（一家医疗设备公司）。从1995年到1998年他担任Healthdyne公司销售与市场部高级副总裁。在此之前，他在Medex公司，美达，巴克斯特Edwards和DeRoyal产业担任多个销售与市场职位。他现在是赖特医疗集团有限公司和登士柏国际公司董事以及呼吸技术公司董事长。他也是匹兹堡动物园及PPG水族馆和汉堡王癌症关怀中心董事。他持有爱荷华大学市场学士学位。
- John L. Miclot joined our board of directors as a non-executive director in October 2015 in connection with the Wright/Tornier merger. Mr. Miclot was a member of the board of directors of Wright Medical Group, Inc. from 2007 to 2015. Mr. Miclot has served as President and Chief Executive Officer and a member of the board of directors of LinguaFlex, Inc., a medical device company focused on treatment of sleep disordered breathing, since August 2015. From December 2011 to December 2014 he served as Chief Executive Officer and a member of the board of directors of Tengion Inc., a publicly held company that focused on organ and cell regeneration. Prior to joining Tengion, Mr. Miclot was an Executive-in Residence at Warburg Pincus, LLC. From 2008 to 2010 he was President and Chief Executive Officer of CCS Medical, Inc., a provider of products and services for patients with chronic diseases. From 2003 until 2008 he served as President and Chief Executive Officer of Respironics, Inc., a provider of sleep and respiratory products, and prior to such time, served in various positions at Respironics, Inc. from 1998 to 2003 including Chief Strategic Officer and President of the Homecare Division. From 1995 to 1998 he served as Senior Vice President, Sales and Marketing of Healthdyne Technologies, Inc., a medical device company that was acquired by Respironics, Inc. in 1998. Mr. Miclot spent the early part of his medical career at DeRoyal Industries, Inc., Baxter International Inc., Ohmeda Medical, Inc. and Medix Inc. Mr. Miclot serves as a director of the Pittsburgh Zoo and PPG Aquarium, charitable and educational institutions, serves on the University of Iowa Tippie College of Business board of advisors and serves as an industrial advisor to EQT Partners, an investment company. Mr. Miclot previously served as Chairman and a member of the board of directors of Breathe Technologies, Inc., a privately held company, prior to its acquisition by Hill-Rom Holdings, Inc. in September 2019. Mr. Miclot previously served on the board of directors of DENTSPLY International Inc., a dental products company, prior to its merger with Sirona Dental Systems, Inc. in February 2016 and ev3 Inc., a global endovascular device company, prior to the sale of the company in 2010.
- David D. Stevens
-
David D. Stevens，2012年6月开始担任公司董事。目前，他在一家私人股本公司担任私人顾问和投资家。从2004年开始，他担任Wright Medical Group公司董事，这是一家上市的骨科公司，设计、制造和分销下肢和生物方案。从2012年开始，他担任Viasystems Group公司董事，这是一家复杂的多层印刷电路板及电气机械方案供应商。他也是多家私人健康医疗公司董事。从2005年到2006年，他担任Accredo Health Group公司首席执行官，这是Medco Health Solutions公司的子公司。从1995年到2005年，他担任Accredo Health公司董事会主席和首席执行官。从1983年到1996年，他担任Accredo Health的前身公司总裁和首席运营官。从2006年到2012年，他担任Medco Health Solutions公司董事。从2004年到2012年，他担任Thomas & Betts公司董事。
David D. Stevens joined Wright Medical Group N.V. board of directors as a non-executive director in October 2015 in connection with the Wright/Tornier merger. Mr. Stevens serves as Wright Medical Group N.V. Chairman. Mr. Stevens was a member of the board of directors of Wright Medical Group, Inc. from 2004 to 2015 and served as Chairman of the Board from 2009 to October 2015 and interim Chief Executive Officer of Wright from April 2011 to September 2011. He has been a private investor since 2006. Mr. Stevens served as Chief Executive Officer of Accredo Health Group, Inc., a subsidiary of Medco Health Solutions, Inc., from 2005 to 2006. He was Chief Executive Officer of Accredo Health, Inc. from 1996 to 2005 served as Chairman of the Board from 1999 to 2005 and was President and Chief Operating Officer of the predecessor companies of Accredo Health from their inception in 1983 until 1996. He serves on the board of directors of Allscripts Healthcare Solutions, Inc., a publicly held company. He previously served on the board of directors of Viasystems Group, Inc., a publicly held company, from 2012 until May 2015 when it was acquired by TTM Technologies, Inc., Medco Health Solutions, Inc., a publicly held company, from 2006 until 2012 when it was acquired by Express Scripts Holding Company, and Thomas & Betts Corporation, a publicly held company, from 2004 to 2012 when it was acquired by ABB Ltd. - David D. Stevens，2012年6月开始担任公司董事。目前，他在一家私人股本公司担任私人顾问和投资家。从2004年开始，他担任Wright Medical Group公司董事，这是一家上市的骨科公司，设计、制造和分销下肢和生物方案。从2012年开始，他担任Viasystems Group公司董事，这是一家复杂的多层印刷电路板及电气机械方案供应商。他也是多家私人健康医疗公司董事。从2005年到2006年，他担任Accredo Health Group公司首席执行官，这是Medco Health Solutions公司的子公司。从1995年到2005年，他担任Accredo Health公司董事会主席和首席执行官。从1983年到1996年，他担任Accredo Health的前身公司总裁和首席运营官。从2006年到2012年，他担任Medco Health Solutions公司董事。从2004年到2012年，他担任Thomas & Betts公司董事。
- David D. Stevens joined Wright Medical Group N.V. board of directors as a non-executive director in October 2015 in connection with the Wright/Tornier merger. Mr. Stevens serves as Wright Medical Group N.V. Chairman. Mr. Stevens was a member of the board of directors of Wright Medical Group, Inc. from 2004 to 2015 and served as Chairman of the Board from 2009 to October 2015 and interim Chief Executive Officer of Wright from April 2011 to September 2011. He has been a private investor since 2006. Mr. Stevens served as Chief Executive Officer of Accredo Health Group, Inc., a subsidiary of Medco Health Solutions, Inc., from 2005 to 2006. He was Chief Executive Officer of Accredo Health, Inc. from 1996 to 2005 served as Chairman of the Board from 1999 to 2005 and was President and Chief Operating Officer of the predecessor companies of Accredo Health from their inception in 1983 until 1996. He serves on the board of directors of Allscripts Healthcare Solutions, Inc., a publicly held company. He previously served on the board of directors of Viasystems Group, Inc., a publicly held company, from 2012 until May 2015 when it was acquired by TTM Technologies, Inc., Medco Health Solutions, Inc., a publicly held company, from 2006 until 2012 when it was acquired by Express Scripts Holding Company, and Thomas & Betts Corporation, a publicly held company, from 2004 to 2012 when it was acquired by ABB Ltd.
高管简历
中英对照 | 中文 | 英文- Kevin D. Cordell
Kevin D. Cordell，他于2014年9月成为我们的总裁，负责美国四肢业务。加入我们之前，他曾担任Covidien Public Limited Company（全球领先的医疗保健产品的公司）的销售副总裁，负责胃肠道解决方案业务（从2012年5月到2014年9月）。任职Covidien公司之前，他也曾担任销售和全球销售副总裁，负责外周血管业务（从2010年7月到2012年5月）。他于2010年加入Covidien公司，通过收购ev3公司，在那里他曾担任美国销售副总裁（从2009年1月到2010年7月）。加入ev3公司之前，他曾担任FoxHollow Technologies公司的副总裁，负责全球销售（从2007年3月到2007年10月）。职业生涯早期，他也曾担任 Johnson & Johnson公司的Cordis Cardiology公司、Centocor公司的多种职务，并不断被提拔。他持有the University of Oklahoma的财务学士学位。他目前任职于TissueGen公司（植入式给药生物可降解聚合物技术的民营开发商）的董事会。
Kevin D. Cordell was appointed our Executive Vice President, Chief Global Commercial Officer in January 2019. Prior to such position, he served as President, U.S. June 2016 to December 2018. From October 2015 to June 2016 he served as our President, Lower Extremities and Biologics. Mr. Cordell served as President, U.S. Extremities of Wright Medical Group, Inc. from September 2014 to October 2015. Prior to joining legacy Wright, Mr. Cordell served as Vice President of Sales for the GI Solutions business at Covidien plc, a global healthcare products company, from May 2012 to September 2014. While at Covidien, he served as Vice President of Sales and Global Marketing for its Peripheral Vascular business from July 2010 to May 2012. He joined Covidien in July 2010 through the acquisition of ev3 Inc., a global endovascular device company, where he served as Vice President of U.S. Sales from January 2009 to July 2010. Prior to ev3 Mr. Cordell served as Vice President, Global Sales of FoxHollow Technologies, Inc. from March 2007 until it was acquired by ev3 in October 2007. Earlier in his career, Mr. Cordell held various positions of increasing responsibility for Johnson & Johnson's Cordis Cardiology and Centocor companies. Mr. Cordell currently serves on the University of Oklahoma Healthcare Board. Mr. Cordell previously served on the board of directors of TissueGen, Inc., a privately-held developer of biodegradable polymer technology for implantable drug delivery.- Kevin D. Cordell，他于2014年9月成为我们的总裁，负责美国四肢业务。加入我们之前，他曾担任Covidien Public Limited Company（全球领先的医疗保健产品的公司）的销售副总裁，负责胃肠道解决方案业务（从2012年5月到2014年9月）。任职Covidien公司之前，他也曾担任销售和全球销售副总裁，负责外周血管业务（从2010年7月到2012年5月）。他于2010年加入Covidien公司，通过收购ev3公司，在那里他曾担任美国销售副总裁（从2009年1月到2010年7月）。加入ev3公司之前，他曾担任FoxHollow Technologies公司的副总裁，负责全球销售（从2007年3月到2007年10月）。职业生涯早期，他也曾担任 Johnson & Johnson公司的Cordis Cardiology公司、Centocor公司的多种职务，并不断被提拔。他持有the University of Oklahoma的财务学士学位。他目前任职于TissueGen公司（植入式给药生物可降解聚合物技术的民营开发商）的董事会。
- Kevin D. Cordell was appointed our Executive Vice President, Chief Global Commercial Officer in January 2019. Prior to such position, he served as President, U.S. June 2016 to December 2018. From October 2015 to June 2016 he served as our President, Lower Extremities and Biologics. Mr. Cordell served as President, U.S. Extremities of Wright Medical Group, Inc. from September 2014 to October 2015. Prior to joining legacy Wright, Mr. Cordell served as Vice President of Sales for the GI Solutions business at Covidien plc, a global healthcare products company, from May 2012 to September 2014. While at Covidien, he served as Vice President of Sales and Global Marketing for its Peripheral Vascular business from July 2010 to May 2012. He joined Covidien in July 2010 through the acquisition of ev3 Inc., a global endovascular device company, where he served as Vice President of U.S. Sales from January 2009 to July 2010. Prior to ev3 Mr. Cordell served as Vice President, Global Sales of FoxHollow Technologies, Inc. from March 2007 until it was acquired by ev3 in October 2007. Earlier in his career, Mr. Cordell held various positions of increasing responsibility for Johnson & Johnson's Cordis Cardiology and Centocor companies. Mr. Cordell currently serves on the University of Oklahoma Healthcare Board. Mr. Cordell previously served on the board of directors of TissueGen, Inc., a privately-held developer of biodegradable polymer technology for implantable drug delivery.
- J. Wesley Porter
J. Wesley Porter，他于2014年10月被任命为高级副总裁兼首席合规官。他于2014年7月加入我们，担任合规副总裁。加入我们之前，他曾担任Smith & Nephew公司（位于孟菲斯）的高级公司法律顾问，负责合规、HIPAA和报销（从2006年4月到2009年5月）。此外，他曾担任CareFusion Corp.的副总裁，负责道德与合规（从2009年6月到2012年9月），以及Allergan公司的副总裁兼副合规官（从2012年9月到2014年2月）。
J. Wesley Porter was appointed our Senior Vice President and Chief Compliance Officer in October 2015 in connection with the Wright/Tornier merger. Mr. Porter joined Wright Medical Group, Inc. in July 2014 as Vice President, Compliance and became Senior Vice President and Chief Compliance Officer in October 2014. Prior to joining legacy Wright, Mr. Porter served as Vice President, Deputy Compliance Officer of Allergan, Inc. from September 2012 to February 2014 Vice President, Ethics and Compliance of CareFusion Corp. from June 2009 to September 2012 and Senior Corporate Counsel, Compliance, HIPAA and Reimbursement of Smith & Nephew, Inc. from April 2006 to May 2009.- J. Wesley Porter，他于2014年10月被任命为高级副总裁兼首席合规官。他于2014年7月加入我们，担任合规副总裁。加入我们之前，他曾担任Smith & Nephew公司（位于孟菲斯）的高级公司法律顾问，负责合规、HIPAA和报销（从2006年4月到2009年5月）。此外，他曾担任CareFusion Corp.的副总裁，负责道德与合规（从2009年6月到2012年9月），以及Allergan公司的副总裁兼副合规官（从2012年9月到2014年2月）。
- J. Wesley Porter was appointed our Senior Vice President and Chief Compliance Officer in October 2015 in connection with the Wright/Tornier merger. Mr. Porter joined Wright Medical Group, Inc. in July 2014 as Vice President, Compliance and became Senior Vice President and Chief Compliance Officer in October 2014. Prior to joining legacy Wright, Mr. Porter served as Vice President, Deputy Compliance Officer of Allergan, Inc. from September 2012 to February 2014 Vice President, Ethics and Compliance of CareFusion Corp. from June 2009 to September 2012 and Senior Corporate Counsel, Compliance, HIPAA and Reimbursement of Smith & Nephew, Inc. from April 2006 to May 2009.
- Lance A. Berry
Lance A. Berry ，2015年10月被任命为Tornier N.V.高级副总裁和财务总监，在Wright/Tornier合并之时。2009年起，担任Wright Medical Group, Inc.的高级副总裁和财务总监。2002年加入legacy Wright，一直到任命财务总监，担任副总裁和企业总会计师。此前，1995-2002年，他担任Arthur Andersen LLP的Tennessee州Memphis港 办事处担任审计经理。他是一名注册会计师，非执业。
Lance A. Berry,has served as the Company's Chief Financial Officer and Treasurer since his appointment on December 4, 2023. Prior to joining the Company, Mr. Berry most recently served from January 2019 until November 2020 as the Executive Vice President, Chief Financial and Operations Officer of Wright Medical Group N.V. ("Wright"), until it was acquired by Stryker in November 2020. Previously, Mr. Berry served as the Senior Vice President, Chief Financial Officer for Wright from 2009 to 2018 and as its Vice President, Corporate Controller from 2002 to 2009. Before joining Wright in 2002, Mr. Berry served as a certified public accountant for Arthur Andersen. Mr. Berry currently serves on the board of directors of a public company, Treace Medical Concepts, Inc. Mr. Berry earned bachelor's and master's degrees in accounting from the University of Mississippi in 1994 and 1995, respectively.- Lance A. Berry ，2015年10月被任命为Tornier N.V.高级副总裁和财务总监，在Wright/Tornier合并之时。2009年起，担任Wright Medical Group, Inc.的高级副总裁和财务总监。2002年加入legacy Wright，一直到任命财务总监，担任副总裁和企业总会计师。此前，1995-2002年，他担任Arthur Andersen LLP的Tennessee州Memphis港 办事处担任审计经理。他是一名注册会计师，非执业。
- Lance A. Berry,has served as the Company's Chief Financial Officer and Treasurer since his appointment on December 4, 2023. Prior to joining the Company, Mr. Berry most recently served from January 2019 until November 2020 as the Executive Vice President, Chief Financial and Operations Officer of Wright Medical Group N.V. ("Wright"), until it was acquired by Stryker in November 2020. Previously, Mr. Berry served as the Senior Vice President, Chief Financial Officer for Wright from 2009 to 2018 and as its Vice President, Corporate Controller from 2002 to 2009. Before joining Wright in 2002, Mr. Berry served as a certified public accountant for Arthur Andersen. Mr. Berry currently serves on the board of directors of a public company, Treace Medical Concepts, Inc. Mr. Berry earned bachelor's and master's degrees in accounting from the University of Mississippi in 1994 and 1995, respectively.
- Peter S. Cooke
Peter S. Cooke，2015年10月被任命为我们国际副总裁，在Wright/Tornier 合并之时。2014年1月-2015年10月，担任Wright Medical Group, Inc. 的国际总裁；2013年1月-2014年1月，担任国际高级副总裁。此前，2010年-2013年1月，在一家全球医疗产品公司 Covidien plc担任副总裁和血管疗法新兴市场总经理。此前，2008年7月-2010年7月，他在一家于2010年7月被Covidien 收购的全球血管内设备公司-ev3 Inc.担任不同的总务管理职位；2006年11月-2008年6月，担任副总裁和国际总经理；2005年1月-2006年11月，担任全球销售副总裁；2003年2月-2005年1月，担任亚太和中国地区总监。此前，他在Guidant Corporation 11年，在Baxter Healthcare Corporation 3年，在St. Jude Medical, Inc.2年。
Peter S. Cooke was appointed our President, Emerging Markets, Australia and Japan in January 2019. Prior to such position, he served as President, International from October 2015 to December 2018. He was appointed to that position in connection with the Wright/Tornier merger. Mr. Cooke served as President, International of Wright Medical Group, Inc. from January 2014 to October 2015 and served as Senior Vice President, International from January 2013 to January 2014. Prior to joining legacy Wright, Mr. Cooke served as Vice President and General Manager, Vascular Therapies Emerging Markets of Covidien plc, a global healthcare products company, from July 2010 to January 2013. Prior to Covidien, Mr. Cooke served in various general management roles for ev3 Inc., a global endovascular device company acquired by Covidien in July 2010 including Vice President and General Manager, International from July 2008 to July 2010; Vice President, General Manager, International from November 2006 to June 2008; Vice President, Sales International from January 2005 until November 2006; and Regional Director Asia Pacific and China from February 2003 until January 2005. Prior to ev3 Mr. Cooke spent eleven years at Guidant Corporation, three years at Baxter Healthcare Corporation and two years at St. Jude Medical, Inc.- Peter S. Cooke，2015年10月被任命为我们国际副总裁，在Wright/Tornier 合并之时。2014年1月-2015年10月，担任Wright Medical Group, Inc. 的国际总裁；2013年1月-2014年1月，担任国际高级副总裁。此前，2010年-2013年1月，在一家全球医疗产品公司 Covidien plc担任副总裁和血管疗法新兴市场总经理。此前，2008年7月-2010年7月，他在一家于2010年7月被Covidien 收购的全球血管内设备公司-ev3 Inc.担任不同的总务管理职位；2006年11月-2008年6月，担任副总裁和国际总经理；2005年1月-2006年11月，担任全球销售副总裁；2003年2月-2005年1月，担任亚太和中国地区总监。此前，他在Guidant Corporation 11年，在Baxter Healthcare Corporation 3年，在St. Jude Medical, Inc.2年。
- Peter S. Cooke was appointed our President, Emerging Markets, Australia and Japan in January 2019. Prior to such position, he served as President, International from October 2015 to December 2018. He was appointed to that position in connection with the Wright/Tornier merger. Mr. Cooke served as President, International of Wright Medical Group, Inc. from January 2014 to October 2015 and served as Senior Vice President, International from January 2013 to January 2014. Prior to joining legacy Wright, Mr. Cooke served as Vice President and General Manager, Vascular Therapies Emerging Markets of Covidien plc, a global healthcare products company, from July 2010 to January 2013. Prior to Covidien, Mr. Cooke served in various general management roles for ev3 Inc., a global endovascular device company acquired by Covidien in July 2010 including Vice President and General Manager, International from July 2008 to July 2010; Vice President, General Manager, International from November 2006 to June 2008; Vice President, Sales International from January 2005 until November 2006; and Regional Director Asia Pacific and China from February 2003 until January 2005. Prior to ev3 Mr. Cooke spent eleven years at Guidant Corporation, three years at Baxter Healthcare Corporation and two years at St. Jude Medical, Inc.
- Timothy L. Lanier
TimothyL.Lanier于2016年6月被任命为我们的上肢总裁。Lanier先生在小型和大型公司的医疗设备和商业运营方面拥有超过25年的经验，其中包括各种医疗专业，例如骨科，血管，肿瘤学和眼科。加入Wright之前，Lanier从2013年9月到2016年6月担任DFine Inc.（一家致力于治疗脊柱转移性肿瘤和其他疾病的公司）销售Vice President。Lanier从2010年7月到2013年9月担任Covidien plc（一家全球梦百合产品公司）血管内部门美国销售Vice President，在那里他建立了一家世界级的销售机构，致力于治疗动脉和静脉疾病。他于2010年7月通过收购EV3Inc.加入Covidien，在那里他从2008年1月到2010年7月担任Area Vice President。在加入EV3之前，Lanier先生从2007年1月到2008年1月担任Anulex Technologies，Inc.商业运营Vice President。1997年至2007年，他还在Zimmer Orthopedics、Spine Division和Spine-Tech，Inc.担任越来越多的执行职务，包括商业运营的Vice President。
Timothy L. Lanier was appointed our President, Upper Extremities in June 2016. Mr. Lanier has over 25 years of experience in medical device and commercial operations in both small and large companies that include various medical specialties such as orthopedics, vascular, oncology and ophthalmology. Prior to joining Wright, from September 2013 to June 2016 Mr. Lanier served as Vice President of Sales of DFINE Inc., a company committed to the treatment of metastatic tumors and other diseases of the spine. From July 2010 to September 2013 Mr. Lanier served as Vice President of US Sales for the Endovascular Division of Covidien plc, a global healthcare products company, where he built a world-class sales organization dedicated to treating both arterial and venous disease. He joined Covidien in July 2010 through the acquisition of ev3 Inc., where he served as Area Vice President from January 2008 to July 2010. Prior to ev3 Mr. Lanier served as Vice President of Commercial Operations at Anulex Technologies, Inc. from January 2007 to January 2008. He also had increasing executive responsibility at Zimmer Orthopedics, Spine Division and Spine-Tech, Inc. from 1997 to 2007 including Vice President of Commercial Operations.- TimothyL.Lanier于2016年6月被任命为我们的上肢总裁。Lanier先生在小型和大型公司的医疗设备和商业运营方面拥有超过25年的经验，其中包括各种医疗专业，例如骨科，血管，肿瘤学和眼科。加入Wright之前，Lanier从2013年9月到2016年6月担任DFine Inc.（一家致力于治疗脊柱转移性肿瘤和其他疾病的公司）销售Vice President。Lanier从2010年7月到2013年9月担任Covidien plc（一家全球梦百合产品公司）血管内部门美国销售Vice President，在那里他建立了一家世界级的销售机构，致力于治疗动脉和静脉疾病。他于2010年7月通过收购EV3Inc.加入Covidien，在那里他从2008年1月到2010年7月担任Area Vice President。在加入EV3之前，Lanier先生从2007年1月到2008年1月担任Anulex Technologies，Inc.商业运营Vice President。1997年至2007年，他还在Zimmer Orthopedics、Spine Division和Spine-Tech，Inc.担任越来越多的执行职务，包括商业运营的Vice President。
- Timothy L. Lanier was appointed our President, Upper Extremities in June 2016. Mr. Lanier has over 25 years of experience in medical device and commercial operations in both small and large companies that include various medical specialties such as orthopedics, vascular, oncology and ophthalmology. Prior to joining Wright, from September 2013 to June 2016 Mr. Lanier served as Vice President of Sales of DFINE Inc., a company committed to the treatment of metastatic tumors and other diseases of the spine. From July 2010 to September 2013 Mr. Lanier served as Vice President of US Sales for the Endovascular Division of Covidien plc, a global healthcare products company, where he built a world-class sales organization dedicated to treating both arterial and venous disease. He joined Covidien in July 2010 through the acquisition of ev3 Inc., where he served as Area Vice President from January 2008 to July 2010. Prior to ev3 Mr. Lanier served as Vice President of Commercial Operations at Anulex Technologies, Inc. from January 2007 to January 2008. He also had increasing executive responsibility at Zimmer Orthopedics, Spine Division and Spine-Tech, Inc. from 1997 to 2007 including Vice President of Commercial Operations.
- Patrick Fisher
Patrick Fisher于2016年6月被任命为我们的下肢总裁。2015年10月至2016年6月，费舍尔先生担任我们的美国销售Vice President。从2012年10月至2015年10月，费舍尔先生担任Wright MedicalGroup，Inc.美国销售Vice President，从2010年10月至2012年10月，费舍尔先生担任西部地区销售区域Vice President。Fisher从2002年7月到2010年10月在Wright担任多个商业和营销职位。2002年7月加入Wright之前，Fisher在Smith&Nephew，Inc.（一家全球医疗技术公司）担任多个职位。Fisher先生任职于University of Tennessee Health Sciences Center Research Foundation的顾问委员会。
Patrick Fisher was appointed our President, Lower Extremities in June 2016. From October 2015 to June 2016 Mr. Fisher served as our Vice President, U.S. Sales. From October 2012 to October 2015 Mr. Fisher served as Vice President, U.S. Sales of Wright Medical Group, Inc., and from October 2010 to October 2012 Mr. Fisher served as Regional Vice President of Sales-West Region. From July 2002 to October 2010 Mr. Fisher served in various commercial and marketing roles within Wright. Prior to joining Wright in July 2002 Mr. Fisher held various positions within Smith & Nephew, Inc., a global medical technology company. Mr. Fisher serves on the advisory board for the University of Tennessee Health Sciences Center Research Foundation.- Patrick Fisher于2016年6月被任命为我们的下肢总裁。2015年10月至2016年6月，费舍尔先生担任我们的美国销售Vice President。从2012年10月至2015年10月，费舍尔先生担任Wright MedicalGroup，Inc.美国销售Vice President，从2010年10月至2012年10月，费舍尔先生担任西部地区销售区域Vice President。Fisher从2002年7月到2010年10月在Wright担任多个商业和营销职位。2002年7月加入Wright之前，Fisher在Smith&Nephew，Inc.（一家全球医疗技术公司）担任多个职位。Fisher先生任职于University of Tennessee Health Sciences Center Research Foundation的顾问委员会。
- Patrick Fisher was appointed our President, Lower Extremities in June 2016. From October 2015 to June 2016 Mr. Fisher served as our Vice President, U.S. Sales. From October 2012 to October 2015 Mr. Fisher served as Vice President, U.S. Sales of Wright Medical Group, Inc., and from October 2010 to October 2012 Mr. Fisher served as Regional Vice President of Sales-West Region. From July 2002 to October 2010 Mr. Fisher served in various commercial and marketing roles within Wright. Prior to joining Wright in July 2002 Mr. Fisher held various positions within Smith & Nephew, Inc., a global medical technology company. Mr. Fisher serves on the advisory board for the University of Tennessee Health Sciences Center Research Foundation.
- Jason D. Asper
JasonD.Asper于2019年4月被任命为我们的高级副总裁，首席数字官。在此之前，他于2019年2月至2019年4月担任高级副总裁，战略，企业发展和技术，并于2017年8月至2019年2月担任高级副总裁，战略和企业发展。在加入Wright之前，Asper先生于2012年9月至2017年7月担任全球咨询公司Deloitte Consulting，LLP的负责人。
Jason D. Asper was appointed our Senior Vice President, Chief Digital Officer in April 2019. Prior to this position, he served as Senior Vice President, Strategy, Corporate Development and Technology from February 2019 to April 2019 and Senior Vice President, Strategy and Corporate Development from August 2017 to February 2019. Prior to joining Wright, Mr. Asper served as a principal for Deloitte Consulting, LLP, a global consulting company, from September 2012 to July 2017.- JasonD.Asper于2019年4月被任命为我们的高级副总裁，首席数字官。在此之前，他于2019年2月至2019年4月担任高级副总裁，战略，企业发展和技术，并于2017年8月至2019年2月担任高级副总裁，战略和企业发展。在加入Wright之前，Asper先生于2012年9月至2017年7月担任全球咨询公司Deloitte Consulting，LLP的负责人。
- Jason D. Asper was appointed our Senior Vice President, Chief Digital Officer in April 2019. Prior to this position, he served as Senior Vice President, Strategy, Corporate Development and Technology from February 2019 to April 2019 and Senior Vice President, Strategy and Corporate Development from August 2017 to February 2019. Prior to joining Wright, Mr. Asper served as a principal for Deloitte Consulting, LLP, a global consulting company, from September 2012 to July 2017.
- Julie D. Dewey
JulieD.Dewey于2015年10月被任命为Wright/Tornier合并后的高级副总裁，首席通信官。杜威女士于2011年10月至2015年10月担任Wright MedicalGroup，Inc.高级副总裁，首席传播官。在加入Legacy Wright之前，杜威女士于2011年3月至2011年10月担任Epocrates，Inc.的首席传播官，该公司是一家上市公司，销售用于临床内容，实践工具和健康行业参与的医生平台。2008年1月至2010年7月，杜威女士担任EV3Inc.的高级副总裁兼首席通信官。在EV3之前，Dewey女士于2003年1月至2007年11月在Kyphon Inc.担任营销和投资者关系职位，并于1998年1月至2003年1月在Thoratec Corporation担任该职位。Dewey女士目前担任美国国家投资者关系研究所（National Investor Relations Institute）的董事会成员，该协会是公司官员和投资者关系顾问的专业协会，负责公司管理层，股东，证券分析师和其他金融界成分之间的沟通。
Julie D. Dewey was appointed our Senior Vice President, Chief Communications Officer in October 2015 in connection with the Wright/Tornier merger. Ms. Dewey served as Senior Vice President, Chief Communications Officer of Wright Medical Group, Inc. from October 2011 to October 2015. Prior to joining legacy Wright, Ms. Dewey served as Chief Communications Officer of Epocrates, Inc., a publicly held company that sold physician platforms for clinical content, practice tools and health industry engagement, from March 2011 to October 2011. From January 2008 to July 2010 Ms. Dewey was Senior Vice President and Chief Communications Officer of ev3 Inc. Prior to ev3 Ms. Dewey held marketing and investor relations positions at Kyphon Inc. from January 2003 to November 2007 and Thoratec Corporation from January 1998 to January 2003. Ms. Dewey currently serves as a member of the board of directors for the National Investor Relations Institute, the professional association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents.- JulieD.Dewey于2015年10月被任命为Wright/Tornier合并后的高级副总裁，首席通信官。杜威女士于2011年10月至2015年10月担任Wright MedicalGroup，Inc.高级副总裁，首席传播官。在加入Legacy Wright之前，杜威女士于2011年3月至2011年10月担任Epocrates，Inc.的首席传播官，该公司是一家上市公司，销售用于临床内容，实践工具和健康行业参与的医生平台。2008年1月至2010年7月，杜威女士担任EV3Inc.的高级副总裁兼首席通信官。在EV3之前，Dewey女士于2003年1月至2007年11月在Kyphon Inc.担任营销和投资者关系职位，并于1998年1月至2003年1月在Thoratec Corporation担任该职位。Dewey女士目前担任美国国家投资者关系研究所（National Investor Relations Institute）的董事会成员，该协会是公司官员和投资者关系顾问的专业协会，负责公司管理层，股东，证券分析师和其他金融界成分之间的沟通。
- Julie D. Dewey was appointed our Senior Vice President, Chief Communications Officer in October 2015 in connection with the Wright/Tornier merger. Ms. Dewey served as Senior Vice President, Chief Communications Officer of Wright Medical Group, Inc. from October 2011 to October 2015. Prior to joining legacy Wright, Ms. Dewey served as Chief Communications Officer of Epocrates, Inc., a publicly held company that sold physician platforms for clinical content, practice tools and health industry engagement, from March 2011 to October 2011. From January 2008 to July 2010 Ms. Dewey was Senior Vice President and Chief Communications Officer of ev3 Inc. Prior to ev3 Ms. Dewey held marketing and investor relations positions at Kyphon Inc. from January 2003 to November 2007 and Thoratec Corporation from January 1998 to January 2003. Ms. Dewey currently serves as a member of the board of directors for the National Investor Relations Institute, the professional association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents.
- Kevin C. Smith
KevinC.Smith于2018年3月被任命为我们的高级副总裁，质量和监管机构。从2012年5月至2018年2月，史密斯先生担任我们的Vice President，全球质量和法规事务。在加入Wright之前，Smith先生从2001年12月到2012年5月担任波士顿科学国际有限公司（一家全球医疗技术公司）质量系统Corporate Director。
Kevin C. Smith was appointed our Senior Vice President, Quality and Regulatory in March 2018. From May 2012 to February 2018 Mr. Smith served as our Vice President, Global Quality and Regulatory Affairs. Prior to joining Wright, Mr. Smith served as Corporate Director, Quality Systems for Boston Scientific Corporation, a global medical technology company, from December 2001 to May 2012.- KevinC.Smith于2018年3月被任命为我们的高级副总裁，质量和监管机构。从2012年5月至2018年2月，史密斯先生担任我们的Vice President，全球质量和法规事务。在加入Wright之前，Smith先生从2001年12月到2012年5月担任波士顿科学国际有限公司（一家全球医疗技术公司）质量系统Corporate Director。
- Kevin C. Smith was appointed our Senior Vice President, Quality and Regulatory in March 2018. From May 2012 to February 2018 Mr. Smith served as our Vice President, Global Quality and Regulatory Affairs. Prior to joining Wright, Mr. Smith served as Corporate Director, Quality Systems for Boston Scientific Corporation, a global medical technology company, from December 2001 to May 2012.
- Barry J. Regan
Barry J. Regan自2020年11月起担任Dexcom, Inc.全球运营执行副总裁。在加入Dexcom之前，Regan先生于2018年7月至2020年11月担任Wright Medical全球运营高级副总裁。Regan先生于2015年3月至2018年6月担任Smith & Nephew全球供应链与采购高级副总裁。Regan从2013年1月到2015年3月担任AbbVie美国和波多黎各运营副总裁。2013年之前，Regan先生在雅培（Abbott）工作了近19年，担任过各种运营领导职务。Regan先生获得了Limerick大学的技术学士学位和Lake Forest管理研究生院的MBA学位。
Barry J. Regan has served as our Executive Vice President, Global Operations since November 2020. Prior to joining Dexcom, Mr. Regan served as Senior Vice President, Global Operations at Wright Medical from July 2018 to November 2020. From March 2015 to June 2018 Mr. Regan served as Senior Vice President, Global Supply Chain & Procurement at Smith & Nephew. Mr. Regan served as Vice President, US & Puerto Rico Operations at AbbVie from January 2013 to March 2015. Prior to 2013 Mr. Regan spent nearly 19 years with Abbott, in various operations leadership positions. Mr. Regan received a Bachelor of Technology degree from the University of Limerick and an MBA from the Lake Forest Graduate School of Management.- Barry J. Regan自2020年11月起担任Dexcom, Inc.全球运营执行副总裁。在加入Dexcom之前，Regan先生于2018年7月至2020年11月担任Wright Medical全球运营高级副总裁。Regan先生于2015年3月至2018年6月担任Smith & Nephew全球供应链与采购高级副总裁。Regan从2013年1月到2015年3月担任AbbVie美国和波多黎各运营副总裁。2013年之前，Regan先生在雅培（Abbott）工作了近19年，担任过各种运营领导职务。Regan先生获得了Limerick大学的技术学士学位和Lake Forest管理研究生院的MBA学位。
- Barry J. Regan has served as our Executive Vice President, Global Operations since November 2020. Prior to joining Dexcom, Mr. Regan served as Senior Vice President, Global Operations at Wright Medical from July 2018 to November 2020. From March 2015 to June 2018 Mr. Regan served as Senior Vice President, Global Supply Chain & Procurement at Smith & Nephew. Mr. Regan served as Vice President, US & Puerto Rico Operations at AbbVie from January 2013 to March 2015. Prior to 2013 Mr. Regan spent nearly 19 years with Abbott, in various operations leadership positions. Mr. Regan received a Bachelor of Technology degree from the University of Limerick and an MBA from the Lake Forest Graduate School of Management.
- Steven P. Wallace
Steven P.Wallace于2019年1月被任命为我们的国际总裁。2016年11月至2018年12月，华莱士先生担任Wright Extremities Marketing的Vice President。在加入Wright之前，Wallace先生于2015年6月至2016年11月担任骨科公司Zimmer Biomet，Inc.CMF&Thoric Division全球营销和医疗教育Vice President。担任该职位之前，Wallace从2012年6月到2015年5月担任Biomet，Inc.（一家骨科公司，被Zimmer收购）全球营销和业务开发高级主管以及其他多个职位。在加入Biomet公司之前，华莱士先生曾在卡地纳健康集团公司担任多个职位，该公司是一家全球性的综合梦百合服务和产品公司。
Steven P. Wallace was appointed our President, International in January 2019. From November 2016 to December 2018 Mr. Wallace served as Vice President, Extremities Marketing of Wright. Prior to joining Wright, Mr. Wallace served as Vice President of Global Marketing and Medical Education of the CMF & Thoracic Division of Zimmer Biomet, Inc., an orthopedic company, from June 2015 to November 2016. Prior to that position, Mr. Wallace served as Senior Director of Global Marketing and Business Development from June 2012 to May 2015 and various other positions for the Microfixation Division of Biomet, Inc., an orthopedic company acquired by Zimmer. Prior to joining Biomet, Mr. Wallace served in a number of positions for Cardinal Health, Inc., a global, integrated healthcare services and products company.- Steven P.Wallace于2019年1月被任命为我们的国际总裁。2016年11月至2018年12月，华莱士先生担任Wright Extremities Marketing的Vice President。在加入Wright之前，Wallace先生于2015年6月至2016年11月担任骨科公司Zimmer Biomet，Inc.CMF&Thoric Division全球营销和医疗教育Vice President。担任该职位之前，Wallace从2012年6月到2015年5月担任Biomet，Inc.（一家骨科公司，被Zimmer收购）全球营销和业务开发高级主管以及其他多个职位。在加入Biomet公司之前，华莱士先生曾在卡地纳健康集团公司担任多个职位，该公司是一家全球性的综合梦百合服务和产品公司。
- Steven P. Wallace was appointed our President, International in January 2019. From November 2016 to December 2018 Mr. Wallace served as Vice President, Extremities Marketing of Wright. Prior to joining Wright, Mr. Wallace served as Vice President of Global Marketing and Medical Education of the CMF & Thoracic Division of Zimmer Biomet, Inc., an orthopedic company, from June 2015 to November 2016. Prior to that position, Mr. Wallace served as Senior Director of Global Marketing and Business Development from June 2012 to May 2015 and various other positions for the Microfixation Division of Biomet, Inc., an orthopedic company acquired by Zimmer. Prior to joining Biomet, Mr. Wallace served in a number of positions for Cardinal Health, Inc., a global, integrated healthcare services and products company.
- Jennifer S. Walker
Jennifer S. Walker在2011年12月成为我们过程改进的高级副总裁。在这之前，自2009年12月以来她一直担任我们的副总裁，公司总监。自从在1993年加入我们的金融组织，她还担任过财务报告和风险管理的总监助理，总监；企业所得税和风险管理总监和税务经理。在加入我们之前，Walker女士是Arthur Andersen LLP的一个高级税务员。Walker女士是一个注册会计师。
Jennifer S. Walker was appointed our Senior Vice President, Process Improvement in October 2015 in connection with the Wright/Tornier merger. Ms. Walker served as Senior Vice President, Process Improvement of Wright Medical Group, Inc. from December 2011 to October 2015 and Vice President and Corporate Controller from December 2009 to December 2011. Since joining legacy Wright’s financial organization in 1993 she served as Assistant Controller, Director, Financial Reporting & Risk Management, Director, Corporate Tax & Risk Management, and Tax Manager of legacy Wright. Prior to joining legacy Wright, Ms. Walker was a senior tax accountant with Arthur Andersen LLP. Ms. Walker is a certified public accountant.- Jennifer S. Walker在2011年12月成为我们过程改进的高级副总裁。在这之前，自2009年12月以来她一直担任我们的副总裁，公司总监。自从在1993年加入我们的金融组织，她还担任过财务报告和风险管理的总监助理，总监；企业所得税和风险管理总监和税务经理。在加入我们之前，Walker女士是Arthur Andersen LLP的一个高级税务员。Walker女士是一个注册会计师。
- Jennifer S. Walker was appointed our Senior Vice President, Process Improvement in October 2015 in connection with the Wright/Tornier merger. Ms. Walker served as Senior Vice President, Process Improvement of Wright Medical Group, Inc. from December 2011 to October 2015 and Vice President and Corporate Controller from December 2009 to December 2011. Since joining legacy Wright’s financial organization in 1993 she served as Assistant Controller, Director, Financial Reporting & Risk Management, Director, Corporate Tax & Risk Management, and Tax Manager of legacy Wright. Prior to joining legacy Wright, Ms. Walker was a senior tax accountant with Arthur Andersen LLP. Ms. Walker is a certified public accountant.
- Andrew C. Morton
Andrew C. Morton， 2010年6月加入公司担任人力资源副总裁。加入Hanger之前，他自2006年起在Freescale Semiconductor公司，担任两个职位，第一个是人才和企业服务副总裁；第二个hi人力资源供应链副总裁。从1992年到2006年他在国际商用机器公司公司，担任多个全球领域和企业人力资源执行职位，包括软件，硬件和销售业务。他持有美国科罗拉多大学博尔德分校金融学士学位以及锡拉库萨大学工商管理硕士学位。在两个学位取得的时间中间，他从1988年到1989年在Baxter Healthcare 担任金融职位。
Andrew C. Morton was appointed our Senior Vice President and Chief Human Resources Officer in March 2018. From November 2015 to March 2018 Mr. Morton served as Senior Vice President and Chief Human Resources Officer for Hanger, Inc., a provider of orthotic and prosthetic patient care services and solutions, and served as Vice President and Chief Human Resources Officer of Hanger from June 2010 to November 2015. Prior to joining Hanger, Mr. Morton served in two capacities; first as Vice President Talent and Corporate Services, and then Vice President Human Resources Supply Chain for Freescale Semiconductor, Inc., a designer and manufacturer of embedded processors, from May 2006 to June 2010. From June 1992 to April 2006 Mr. Morton worked at International Business Machines Corporation and held various global field and corporate human resource executive roles of increasing responsibility across its software, hardware and sales businesses.- Andrew C. Morton， 2010年6月加入公司担任人力资源副总裁。加入Hanger之前，他自2006年起在Freescale Semiconductor公司，担任两个职位，第一个是人才和企业服务副总裁；第二个hi人力资源供应链副总裁。从1992年到2006年他在国际商用机器公司公司，担任多个全球领域和企业人力资源执行职位，包括软件，硬件和销售业务。他持有美国科罗拉多大学博尔德分校金融学士学位以及锡拉库萨大学工商管理硕士学位。在两个学位取得的时间中间，他从1988年到1989年在Baxter Healthcare 担任金融职位。
- Andrew C. Morton was appointed our Senior Vice President and Chief Human Resources Officer in March 2018. From November 2015 to March 2018 Mr. Morton served as Senior Vice President and Chief Human Resources Officer for Hanger, Inc., a provider of orthotic and prosthetic patient care services and solutions, and served as Vice President and Chief Human Resources Officer of Hanger from June 2010 to November 2015. Prior to joining Hanger, Mr. Morton served in two capacities; first as Vice President Talent and Corporate Services, and then Vice President Human Resources Supply Chain for Freescale Semiconductor, Inc., a designer and manufacturer of embedded processors, from May 2006 to June 2010. From June 1992 to April 2006 Mr. Morton worked at International Business Machines Corporation and held various global field and corporate human resource executive roles of increasing responsibility across its software, hardware and sales businesses.
- Robert J. Palmisano
Robert J. Palmisano，担任总裁兼首席执行官，并于2011年9月起担任Wright Medical Group, Inc.纳斯达克：WMGI的董事会执行董事和董事会成员，直至2020年11月其被史赛克公司（NYSE：SYK）收购。Palmisano先生于2008年4月至2010年7月被Covidien plc收购时担任ev3 Inc.的总裁兼首席执行官。Palmisano先生于2003年4月至2007年4月被Advanced Medical Optics，Inc.收购时担任IntraLase Corp.的总裁兼首席执行官。在加入IntraLase之前，Palmisano先生于2001年4月至2003年4月担任MacroChem Corporation的总裁兼首席执行官。Palmisano先生于2020年12月至今担任Priveterra Acquisition Corp.（纳斯达克：PMGMU）的董事会主席。Palmisano先生此前曾担任Avedro, Inc.董事会主席，并在ev3 Inc.、Osteotech，Inc.和Abbott Medical Optics，Inc.（均为上市公司）以及博士伦（Bausch & Lomb）（一家私营公司）的董事会任职。Palmisano先生拥有普罗维登斯学院政治学学士学位。
Robert J. Palmisano served as President and Chief Executive Officer, and as the Executive Director of the Board of Directors and Board Member of Wright Medical Group, Inc. Nasdaq: WMGI from September 2011 until its acquisition by Stryker Corporation (NYSE: SYK) in November 2020. Mr. Palmisano served as President and Chief Executive Officer of ev3 Inc. from April 2008 to July 2010 when it was acquired by Covidien plc. Mr. Palmisano was President and Chief Executive Officer of IntraLase Corp. from April 2003 to April 2007 when it was acquired by Advanced Medical Optics, Inc. Before joining IntraLase, Mr. Palmisano was President and Chief Executive Officer of MacroChem Corporation from April 2001 to April 2003. Mr. Palmisano has served as Chairman of the Board of Priveterra Acquisition Corp. (Nasdaq: PMGMU) from December 2020 to present. Mr. Palmisano previously served as the Chairman of the Board of Avedro, Inc., and on the board of directors of ev3 Inc., Osteotech, Inc. and Abbott Medical Optics, Inc., all publicly held companies, and Bausch & Lomb, a privately held company. Mr. Palmisano holds a B.A. in Political Science from Providence College.- Robert J. Palmisano，担任总裁兼首席执行官，并于2011年9月起担任Wright Medical Group, Inc.纳斯达克：WMGI的董事会执行董事和董事会成员，直至2020年11月其被史赛克公司（NYSE：SYK）收购。Palmisano先生于2008年4月至2010年7月被Covidien plc收购时担任ev3 Inc.的总裁兼首席执行官。Palmisano先生于2003年4月至2007年4月被Advanced Medical Optics，Inc.收购时担任IntraLase Corp.的总裁兼首席执行官。在加入IntraLase之前，Palmisano先生于2001年4月至2003年4月担任MacroChem Corporation的总裁兼首席执行官。Palmisano先生于2020年12月至今担任Priveterra Acquisition Corp.（纳斯达克：PMGMU）的董事会主席。Palmisano先生此前曾担任Avedro, Inc.董事会主席，并在ev3 Inc.、Osteotech，Inc.和Abbott Medical Optics，Inc.（均为上市公司）以及博士伦（Bausch & Lomb）（一家私营公司）的董事会任职。Palmisano先生拥有普罗维登斯学院政治学学士学位。
- Robert J. Palmisano served as President and Chief Executive Officer, and as the Executive Director of the Board of Directors and Board Member of Wright Medical Group, Inc. Nasdaq: WMGI from September 2011 until its acquisition by Stryker Corporation (NYSE: SYK) in November 2020. Mr. Palmisano served as President and Chief Executive Officer of ev3 Inc. from April 2008 to July 2010 when it was acquired by Covidien plc. Mr. Palmisano was President and Chief Executive Officer of IntraLase Corp. from April 2003 to April 2007 when it was acquired by Advanced Medical Optics, Inc. Before joining IntraLase, Mr. Palmisano was President and Chief Executive Officer of MacroChem Corporation from April 2001 to April 2003. Mr. Palmisano has served as Chairman of the Board of Priveterra Acquisition Corp. (Nasdaq: PMGMU) from December 2020 to present. Mr. Palmisano previously served as the Chairman of the Board of Avedro, Inc., and on the board of directors of ev3 Inc., Osteotech, Inc. and Abbott Medical Optics, Inc., all publicly held companies, and Bausch & Lomb, a privately held company. Mr. Palmisano holds a B.A. in Political Science from Providence College.
- James A. Lightman
James A. Lightman在2011年12月29日被任命为高级副总裁，总法律顾问和秘书。在加入我们之前，Lightman曾在Bausch & Lomb Incorporated担任各种法律和行政职位。Lightman先生从2008年2月到2009年11月担任Bausch & Lomb Incorporated的副总裁兼总法律顾问助理，并且从2011年8月至今一直担任副总裁，全球销售业务主管。从2007年6月到2008年2月，他担任Eyeonics, Inc的副总裁兼总法律顾问。在加入Eyeonics之前，从2005年2月到2007年4月Lightman先生曾担任IntraLase Corp.的高级副总裁兼法律总顾问。
James A. Lightman was appointed our Senior Vice President, General Counsel and Secretary in October 2015 in connection with the Wright/Tornier merger. Mr. Lightman joined Wright Medical Group, Inc. in December 2011 as Senior Vice President, General Counsel and Secretary. Prior to joining legacy Wright, Mr. Lightman served in various legal and executive positions with Bausch & Lomb Incorporated, a privately held supplier of eye health products. From February 2008 to November 2009 Mr. Lightman served as Vice President and Assistant General Counsel of Bausch & Lomb, and held the position of Vice President, Global Sales Operations until August 2011. From June 2007 to February 2008 he served as Vice President and General Counsel of Eyeonics, Inc. Prior to joining Eyeonics, Mr. Lightman served as Senior Vice President and General Counsel of IntraLase Corp. from February 2005 to April 2007.- James A. Lightman在2011年12月29日被任命为高级副总裁，总法律顾问和秘书。在加入我们之前，Lightman曾在Bausch & Lomb Incorporated担任各种法律和行政职位。Lightman先生从2008年2月到2009年11月担任Bausch & Lomb Incorporated的副总裁兼总法律顾问助理，并且从2011年8月至今一直担任副总裁，全球销售业务主管。从2007年6月到2008年2月，他担任Eyeonics, Inc的副总裁兼总法律顾问。在加入Eyeonics之前，从2005年2月到2007年4月Lightman先生曾担任IntraLase Corp.的高级副总裁兼法律总顾问。
- James A. Lightman was appointed our Senior Vice President, General Counsel and Secretary in October 2015 in connection with the Wright/Tornier merger. Mr. Lightman joined Wright Medical Group, Inc. in December 2011 as Senior Vice President, General Counsel and Secretary. Prior to joining legacy Wright, Mr. Lightman served in various legal and executive positions with Bausch & Lomb Incorporated, a privately held supplier of eye health products. From February 2008 to November 2009 Mr. Lightman served as Vice President and Assistant General Counsel of Bausch & Lomb, and held the position of Vice President, Global Sales Operations until August 2011. From June 2007 to February 2008 he served as Vice President and General Counsel of Eyeonics, Inc. Prior to joining Eyeonics, Mr. Lightman served as Senior Vice President and General Counsel of IntraLase Corp. from February 2005 to April 2007.
- Julie B. Andrews
Julie B. Andrews，于2019年8月至2020年12月期间，Andrews女士曾在Wright Medical Group N.V。纳斯达克：WMGI担任全球金融高级副总裁一职，负责财务、会计、税务和财务职能。在Wright医疗任职期间，Andrews女士在几起成功的并购交易中发挥了关键的领导作用。其中包括牵头将髋关节和膝关节业务以约3亿美元出售给Microport的交易剥离和剥离，为Wright医疗以33亿美元的股权价值收购Tornier，N.V。提供领导监督，以及牵头将Wright医疗出售给史赛克 Corp.的尽职调查和整合规划。Andrews女士于2012年5月至2019年9月担任Wright Medical Group N.V。（F.K.a。 赖特医疗集团 Inc.）的副总裁兼首席会计官。在加入Wright医疗之前，Andrews女士在全球医疗器械公司美敦力公司工作了十四年。在美敦力任职期间，Andrews女士担任过多个关键财务职位，包括负责价值35亿美元的脊柱和生物制剂业务的财务副总裁（业务部门CFO）。Andrews女士的职业生涯始于田纳西州孟菲斯市的通贝和伊利诺伊州芝加哥市的Thomas Havey，LLP.Andrews女士目前是Priveterra（纳斯达克：PMGM）的董事会成员，该公司是一家专注于医疗保健的特殊收购公司，并担任其审计委员会主席。Andrews女士获得了西北印第安纳大学会计学学士学位。
Julie B. Andrews from August 2019 to December 2020 Ms. Andrews held the position of Senior Vice President, Global Finance with Wright Medical Group N.V. Nasdaq: WMGI with responsibility for the finance, accounting, tax and treasury functions. During her time at Wright Medical, Ms. Andrews played key leadership roles in several successful mergers and acquisitions. These included leading the divestiture and carve-out of the approximately $300 million sale of the hip and knee business to Microport, providing leadership oversight for Wright Medical's $3.3 billion in equity value acquisition of Tornier, N.V., and leading the diligence and integration planning of the sale of Wright Medical to Stryker Corp. Ms. Andrews was Vice President, Chief Accounting Officer from May 2012 to September 2019 of Wright Medical Group N.V. (f.k.a. Wright Medical Group Inc.). Prior to joining Wright Medical, Ms. Andrews spent fourteen years at Medtronic, Inc., a global medical device company. During her tenure with Medtronic, Ms. Andrews held numerous key financial positions including Vice President, Finance (Business Unit CFO) for the $3.5 billion Spine and Biologics business. Ms. Andrews began her career working with Thomas & Betts Corporation in Memphis, Tennessee and Thomas Havey, LLP in Chicago, Illinois. Ms. Andrews is currently on the board of directors of Priveterra (Nasdaq: PMGM), a healthcare focused special acquisition corporation and serves as the chair of their audit committee. Ms. Andrews received a BS in Accounting from Indiana University NW.- Julie B. Andrews，于2019年8月至2020年12月期间，Andrews女士曾在Wright Medical Group N.V。纳斯达克：WMGI担任全球金融高级副总裁一职，负责财务、会计、税务和财务职能。在Wright医疗任职期间，Andrews女士在几起成功的并购交易中发挥了关键的领导作用。其中包括牵头将髋关节和膝关节业务以约3亿美元出售给Microport的交易剥离和剥离，为Wright医疗以33亿美元的股权价值收购Tornier，N.V。提供领导监督，以及牵头将Wright医疗出售给史赛克 Corp.的尽职调查和整合规划。Andrews女士于2012年5月至2019年9月担任Wright Medical Group N.V。（F.K.a。 赖特医疗集团 Inc.）的副总裁兼首席会计官。在加入Wright医疗之前，Andrews女士在全球医疗器械公司美敦力公司工作了十四年。在美敦力任职期间，Andrews女士担任过多个关键财务职位，包括负责价值35亿美元的脊柱和生物制剂业务的财务副总裁（业务部门CFO）。Andrews女士的职业生涯始于田纳西州孟菲斯市的通贝和伊利诺伊州芝加哥市的Thomas Havey，LLP.Andrews女士目前是Priveterra（纳斯达克：PMGM）的董事会成员，该公司是一家专注于医疗保健的特殊收购公司，并担任其审计委员会主席。Andrews女士获得了西北印第安纳大学会计学学士学位。
- Julie B. Andrews from August 2019 to December 2020 Ms. Andrews held the position of Senior Vice President, Global Finance with Wright Medical Group N.V. Nasdaq: WMGI with responsibility for the finance, accounting, tax and treasury functions. During her time at Wright Medical, Ms. Andrews played key leadership roles in several successful mergers and acquisitions. These included leading the divestiture and carve-out of the approximately $300 million sale of the hip and knee business to Microport, providing leadership oversight for Wright Medical's $3.3 billion in equity value acquisition of Tornier, N.V., and leading the diligence and integration planning of the sale of Wright Medical to Stryker Corp. Ms. Andrews was Vice President, Chief Accounting Officer from May 2012 to September 2019 of Wright Medical Group N.V. (f.k.a. Wright Medical Group Inc.). Prior to joining Wright Medical, Ms. Andrews spent fourteen years at Medtronic, Inc., a global medical device company. During her tenure with Medtronic, Ms. Andrews held numerous key financial positions including Vice President, Finance (Business Unit CFO) for the $3.5 billion Spine and Biologics business. Ms. Andrews began her career working with Thomas & Betts Corporation in Memphis, Tennessee and Thomas Havey, LLP in Chicago, Illinois. Ms. Andrews is currently on the board of directors of Priveterra (Nasdaq: PMGM), a healthcare focused special acquisition corporation and serves as the chair of their audit committee. Ms. Andrews received a BS in Accounting from Indiana University NW.